4.5 Article

Bereavement and the Diagnosis of Major Depressive Episode in the National Epidemiologic Survey on Alcohol and Related Conditions

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 73, Issue 2, Pages 208-215

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.10m06080

Keywords

-

Funding

  1. Abbott
  2. Alkermes
  3. Aspect Medical Systems
  4. AstraZeneca
  5. BioResearch
  6. BrainCells
  7. Bristol-Myers Squibb
  8. Cephalon
  9. CeNeRx BioPharma
  10. Clinical Trials Solutions
  11. Clintara
  12. Covidien
  13. Eli Lilly
  14. EnVivo
  15. Euthymics Bioscience
  16. Forest
  17. Ganeden Biotech
  18. GlaxoSmithKline
  19. Icon Clinical Research
  20. i3 Innovus/Ingenix
  21. Johnson & Johnson Pharmaceutical Research Development
  22. Lichtwer Pharma GmbH
  23. Lorex
  24. National Alliance for Research on Schizophrenia & Depression (NARSAD)
  25. National Center for Complementary and Alternative Medicine
  26. National Institute of Drug Abuse
  27. National Institute of Mental Health
  28. Novartis AG
  29. Organon
  30. PamLab
  31. Pfizer
  32. Pharmavite
  33. Photothera
  34. Roche
  35. RCT Logic
  36. Sanofi-Aventis
  37. Shire
  38. Solvay
  39. Synthelabo
  40. Wyeth-Ayerst
  41. Affectis AG
  42. Amarin Pharma
  43. Auspex
  44. Bayer AG
  45. Best Practice Project Management
  46. BioMarin
  47. Biovail
  48. CNS Response
  49. Compellis
  50. Cypress
  51. DiagnoSearch Life Sciences (P)
  52. Dainippon Sumitomo Pharma
  53. Dov
  54. Edgemont
  55. Eisai
  56. ePharmaSolutions
  57. EPIX
  58. Fabre-Kramer
  59. GenOmind
  60. Grunenthal GmbH
  61. i3 Innovus/Ingenis
  62. Janssen
  63. Jazz
  64. Knoll
  65. Labopharm
  66. Lundbeck
  67. MedAvante
  68. Merck
  69. MSI Methylation Sciences
  70. Naurex
  71. Neuronetics
  72. Next Wave
  73. Nutrition 21
  74. Orexigen Therapeutics
  75. Organon Otsuka
  76. PharmaStar
  77. PharmoRx Therapeutics
  78. Precision Human Biolaboratory
  79. Prexa Pharmaceuticals
  80. Puretech Ventures
  81. PsychoGenics
  82. Psylin Neurosciences
  83. Rexahn
  84. Ridge Diagnostics
  85. Sepracor
  86. Servier Laboratories
  87. Schering-Plough
  88. Somaxon
  89. Somerset
  90. Sunovion
  91. Supernus
  92. Takeda
  93. Tal Medical
  94. Tetragenex
  95. TransForm
  96. Transcept
  97. Vanda
  98. Adamed
  99. Advanced Meeting Partners
  100. American Psychiatric Association
  101. American Society of Clinical Psychopharmacology
  102. Belvoir Media Group
  103. Boehringer Ingelheim GmbH
  104. CME Institute/Physicians Postgraduate Press
  105. Imedex
  106. Massachusetts General Hospital (MGH) Psychiatry Academy/Primedia
  107. MGH Psychiatry Academy/Reed Elsevier
  108. United BioSource
  109. National Institutes of Health [MH087544, DA080887, MH66057]

Ask authors/readers for more resources

Objective: Bereavement-related depression is excluded from a diagnosis of major depressive episode (MDE) in DSM-IV, unless the syndrome is prolonged or complicated. The objective of this study is to assess the validity of the bereavement exclusion by comparing characteristics of bereavement-related episodes that are excluded from a diagnosis and bereavement-related episodes that qualify for a diagnosis (complicated bereavement) to MDE. Method: We used data from 2 waves of the National Epidemiologic Survey on Alcohol and Related Conditions (n = 43,093) to compare bereavement-excluded depression and complicated bereavement to MDE with respect to indicators of preexisting risk for psychopathology (antecedent indicators) and indicators of disorder severity measured at baseline and at the study's 3-year follow-up interview (consequent indicators). The primary outcome measure was the Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV. Results: Compared to individuals with MDE, individuals with bereavement-excluded depression had lower risks of preexisting psychiatric disorders (eg, 0.44 lower odds of social phobia, P = .006), fewer depressive episodes (recurrence rate 0.37 times lower, P < .001), less psychosocial impairment (P < .001), a 0.18 times lower odds of seeking treatment (P < .001), and a lower risk of psychiatric disorders during a 3-year follow-up period. Unexpectedly, this same pattern of differences was observed between individuals with complicated bereavement and MDE. Conclusions: Despite the presence of a clinically significant depressive episode, bereavement-excluded depression is in many ways less indicative of psychopathology than MDE. However, complicated bereavement was more similar to bereavement-excluded depression than to MDE. We therefore question whether the DSM-IV criteria validly distinguish between nondisordered loss reactions (bereavement-excluded depression), pathological loss reactions (complicated bereavement), and nonloss-related MDE. J Clin Psychiatry 2012;73(2):208-215 (C) Copyright 2011 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available